DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
IOFORMINOL
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
IOFORMINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
95FNF21CDN
Molecule Type:
Unknown
Molecular Formula:
C33H40I6N6O15
Molecular Weight:
1522.13
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
PF-05212384
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PF-05212384
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLUBROBENGUANE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FLUBROBENGUANE
×
Maximum Phase:
2
First Approval:
None
UNII:
XCG95AYX3B
Molecule Type:
Small molecule
Molecular Formula:
C11H15BrFN3O
Molecular Weight:
304.16
AlogP:
2.17
PSA:
71.13
HBD:
3.0
HBA:
#RotB:
6.0
Source:
DEXELVUCITABINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
DEXELVUCITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
KU8SPJ271W
Molecule Type:
Small molecule
Molecular Formula:
C9H10FN3O3
Molecular Weight:
227.19
AlogP:
-0.59
PSA:
90.37
HBD:
2.0
HBA:
#RotB:
2.0
Source:
SVN53-67/M57-KLH PEPTIDE VACCINE
2
Protein
Investigational
Unknown
Unknown
Leukemia, Plasma Cell; Multiple Myeloma; Glioblastoma; Gliosarcoma
Unknown
SVN53-67/M57-KLH PEPTIDE VACCINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HU14.18-IL2
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HU14.18-IL2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STX107
2
Small molecule
Investigational
Unknown
Unknown
Fragile X Syndrome
Metabotropic glutamate receptor 5 negative allosteric modulator
STX107
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SPEBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia
Unknown
SPEBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
DRU6NG543J
Molecule Type:
Small molecule
Molecular Formula:
C22H22FN5O3
Molecular Weight:
423.45
AlogP:
4.25
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
10.0
Source:
MK-0533
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Peroxisome proliferator-activated receptor gamma modulator
MK-0533
×
Maximum Phase:
2
First Approval:
None
UNII:
J17152066B
Molecule Type:
Small molecule
Molecular Formula:
C28H24F3NO6
Molecular Weight:
527.5
AlogP:
6.32
PSA:
86.99
HBD:
1.0
HBA:
#RotB:
9.0
Source:
F-18
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
F-18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
HF
Molecular Weight:
19.01
AlogP:
0.15
PSA:
0.0
HBD:
0.0
HBA:
#RotB:
0.0
Source:
QUILIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal; Asthma; Urticaria
Ig epsilon chain C region inhibitor
QUILIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
26F96HRJ3W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMPELOPSIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
AMPELOPSIN
×
Maximum Phase:
2
First Approval:
None
UNII:
KD8QND6427
Molecule Type:
Small molecule
Molecular Formula:
C15H12O8
Molecular Weight:
320.25
AlogP:
0.89
PSA:
147.68
HBD:
6.0
HBA:
#RotB:
1.0
Source:
IRATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Hematologic Neoplasms; Hodgkin Disease
Tumor necrosis factor receptor superfamily member 8 other
IRATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AYH22O1B1U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZUTROMID
2
Small molecule
Investigational
Unknown
Unknown
Muscular Dystrophy, Duchenne
Unknown
EZUTROMID
×
Maximum Phase:
2
First Approval:
None
UNII:
645R07LF0D
Molecule Type:
Small molecule
Molecular Formula:
C19H15NO3S
Molecular Weight:
337.4
AlogP:
4.44
PSA:
60.17
HBD:
0.0
HBA:
#RotB:
3.0
Source:
SCH-486757
2
Small molecule
Investigational
Unknown
Unknown
Cough
Nociceptin receptor agonist
SCH-486757
×
Maximum Phase:
2
First Approval:
None
UNII:
2HV668N62T
Molecule Type:
Small molecule
Molecular Formula:
C24H23Cl2N3O
Molecular Weight:
440.37
AlogP:
5.39
PSA:
49.25
HBD:
1.0
HBA:
#RotB:
4.0
Source:
KB003
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
KB003
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVAROFLOXACIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Bacterial DNA gyrase inhibitor
AVAROFLOXACIN
×
Maximum Phase:
2
First Approval:
None
UNII:
070SV15RJA
Molecule Type:
Small molecule
Molecular Formula:
C21H23F2N3O4
Molecular Weight:
419.43
AlogP:
2.96
PSA:
97.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
A33 131I
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Cell surface A33 antigen binding agent
A33 131I
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANTI-CD18
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ANTI-CD18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DARLEUKIN
2
Protein
Investigational
Unknown
Unknown
Lymphoma, Large B-Cell, Diffuse; Neoplasms
Unknown
DARLEUKIN
×
Maximum Phase:
2
First Approval:
None
UNII:
2OQ3OPV2F8
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEUTERIUM OXIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DEUTERIUM OXIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
J65BV539M3
Molecule Type:
Small molecule
Molecular Formula:
H2O
Molecular Weight:
20.03
AlogP:
-0.82
PSA:
31.5
HBD:
0.0
HBA:
#RotB:
0.0
Source:
S-EQUOL
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
S-EQUOL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROVAFOVIR ETALAFENAMIDE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ROVAFOVIR ETALAFENAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
U8S0IC8DY7
Molecule Type:
Small molecule
Molecular Formula:
C21H24FN6O6P
Molecular Weight:
506.43
AlogP:
2.9
PSA:
152.71
HBD:
2.0
HBA:
#RotB:
10.0
Source:
A6
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
A6
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NIDUFEXOR
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Non-alcoholic Fatty Liver Disease
Bile acid receptor FXR agonist
NIDUFEXOR
×
Maximum Phase:
2
First Approval:
None
UNII:
CJ1PL0TE6J
Molecule Type:
Small molecule
Molecular Formula:
C27H22ClN3O4
Molecular Weight:
487.94
AlogP:
5.17
PSA:
84.66
HBD:
1.0
HBA:
#RotB:
6.0
Source:
GSK-2586881
2
Unknown
Investigational
Unknown
Unknown
Acute Lung Injury; Hypertension, Pulmonary; Severe Acute Respiratory Syndrome
Angiotensinogen hydrolytic enzyme
GSK-2586881
×
Maximum Phase:
2
First Approval:
None
UNII:
FA2I4Z873U
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
J591 177LU
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
J591 177LU
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CRANBERRY LIQUID PREPARATION
2
Unknown
Investigational
Unknown
Unknown
Urinary Tract Infections
Unknown
CRANBERRY LIQUID PREPARATION
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAPROXEN ETEMESIL
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis
Cyclooxygenase inhibitor
NAPROXEN ETEMESIL
×
Maximum Phase:
2
First Approval:
None
UNII:
214269U36R
Molecule Type:
Small molecule
Molecular Formula:
C17H20O5S
Molecular Weight:
336.41
AlogP:
2.54
PSA:
69.67
HBD:
0.0
HBA:
#RotB:
6.0
Source:
SEMORINEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Microtubule-associated protein tau inhibitor
SEMORINEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
O8DG8VI95O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PGA2
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PGA2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RESMINOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Colorectal Neoplasms; Carcinoma, Hepatocellular; Hodgkin Disease; Mycosis Fungoides; Sezary Syndrome
Unknown
RESMINOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
1578EUB98L
Molecule Type:
Small molecule
Molecular Formula:
C16H19N3O4S
Molecular Weight:
349.41
AlogP:
1.31
PSA:
91.64
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ASKP1240
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ASKP1240
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SB-705498
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic; Irritable Bowel Syndrome; Migraine Disorders; Rhinitis; Toothache
Vanilloid receptor antagonist
SB-705498
×
Maximum Phase:
2
First Approval:
None
UNII:
T74V9O0Y2W
Molecule Type:
Small molecule
Molecular Formula:
C17H16BrF3N4O
Molecular Weight:
429.24
AlogP:
4.26
PSA:
57.26
HBD:
2.0
HBA:
#RotB:
3.0
Source:
TRX-1
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
TRX-1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
185
186
187
188
189
190
191
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA